Hemolytic-uremic syndrome epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
(→Age) |
|||
| Line 24: | Line 24: | ||
===Case-fatality rate/Mortality rate=== | ===Case-fatality rate/Mortality rate=== | ||
*In | *In 2017, the incidence of hemolytic uremic syndrome (HUS) is approximately 10% per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%. | ||
*The case-fatality | <nowiki><ref>{{Cite journal</nowiki> | ||
| author = <nowiki>[[Gregory Hall]]</nowiki>, <nowiki>[[Shinichiro Kurosawa]]</nowiki> & <nowiki>[[Deborah J. Stearns-Kurosawa]]</nowiki> | |||
<nowiki> </nowiki><nowiki>|</nowiki> title = Shiga Toxin Therapeutics: Beyond Neutralization | |||
<nowiki> </nowiki><nowiki>|</nowiki> journal = <nowiki>[[Toxins]]</nowiki> | |||
<nowiki> </nowiki><nowiki>|</nowiki> volume = 9 | |||
<nowiki> </nowiki><nowiki>|</nowiki> issue = 9 | |||
<nowiki> </nowiki><nowiki>|</nowiki> year = 2017 | |||
<nowiki> </nowiki><nowiki>|</nowiki> month = September | |||
<nowiki> </nowiki><nowiki>|</nowiki> doi = 10.3390/toxins9090291 | |||
<nowiki> </nowiki><nowiki>|</nowiki> pmid = 28925976 | |||
}}<nowiki></ref></nowiki> | |||
*The case-fatality mortality rate of HUS is approximately 25%. | |||
<nowiki><ref>{{Cite journal</nowiki> | |||
| author = <nowiki>[[Gregory Hall]]</nowiki>, <nowiki>[[Shinichiro Kurosawa]]</nowiki> & <nowiki>[[Deborah J. Stearns-Kurosawa]]</nowiki> | |||
<nowiki> </nowiki><nowiki>|</nowiki> title = Shiga Toxin Therapeutics: Beyond Neutralization | |||
<nowiki> </nowiki><nowiki>|</nowiki> journal = <nowiki>[[Toxins]]</nowiki> | |||
<nowiki> </nowiki><nowiki>|</nowiki> volume = 9 | |||
<nowiki> </nowiki><nowiki>|</nowiki> issue = 9 | |||
<nowiki> </nowiki><nowiki>|</nowiki> year = 2017 | |||
<nowiki> </nowiki><nowiki>|</nowiki> month = September | |||
<nowiki> </nowiki><nowiki>|</nowiki> doi = 10.3390/toxins9090291 | |||
<nowiki> </nowiki><nowiki>|</nowiki> pmid = 28925976 | |||
}}<nowiki></ref></nowiki> | |||
===Age=== | ===Age=== | ||
| Line 35: | Line 57: | ||
===Race=== | ===Race=== | ||
Revision as of 19:50, 26 July 2018
|
Hemolytic-uremic syndrome Microchapters |
|
Differentiating Hemolytic-uremic syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hemolytic-uremic syndrome epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Hemolytic-uremic syndrome epidemiology and demographics |
|
FDA on Hemolytic-uremic syndrome epidemiology and demographics |
|
CDC on Hemolytic-uremic syndrome epidemiology and demographics |
|
Hemolytic-uremic syndrome epidemiology and demographics in the news |
|
Blogs on Hemolytic-uremic syndrome epidemiology and demographics |
|
Risk calculators and risk factors for Hemolytic-uremic syndrome epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Epidemiology and Demographics
Incidence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.[1]
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
is difficult to assess the annual incidence of EHEC‐associated HUS, but overall rates corresponding to two per 100 000 for all age groups have been reported and up to six per 100 000 in children younger than 5 years of age 51.
he incidence in Argentina has been reported to be as high as 12.2 cases per 100 000 children younger than 5 years of age 50. It is difficult to assess the annual incidence of EHEC‐associated HUS, but overall rates corresponding to two per 100 000 for all age groups have been reported and up to six per 100 000 in children younger than 5 years of age 51.
The incidence of hemolytic uremic syndrome (HUS) is approximately 2 per 100,000 individuals worldwide for all age groups.
The prevalence of hemolytic uremic syndrome (HUS) is approximately 6 per 100,000 in children younger than 5 years old.
Prevalence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Case-fatality rate/Mortality rate
- In 2017, the incidence of hemolytic uremic syndrome (HUS) is approximately 10% per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
<ref>{{Cite journal
| author = [[Gregory Hall]], [[Shinichiro Kurosawa]] & [[Deborah J. Stearns-Kurosawa]] | title = Shiga Toxin Therapeutics: Beyond Neutralization | journal = [[Toxins]] | volume = 9 | issue = 9 | year = 2017 | month = September | doi = 10.3390/toxins9090291 | pmid = 28925976 }}</ref>
- The case-fatality mortality rate of HUS is approximately 25%.
<ref>{{Cite journal
| author = [[Gregory Hall]], [[Shinichiro Kurosawa]] & [[Deborah J. Stearns-Kurosawa]] | title = Shiga Toxin Therapeutics: Beyond Neutralization | journal = [[Toxins]] | volume = 9 | issue = 9 | year = 2017 | month = September | doi = 10.3390/toxins9090291 | pmid = 28925976 }}</ref>
Age
- Patients of all age groups may develop hemolytic uremic syndrome (HUS).
- The incidence of HUS increases with age; the median age at diagnosis is younger than 5 years.
- HUS commonly affects individuals younger 5 older than [number of years] years of age.
- [Chronic isease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
Developed Countries
Developing Countries
References
- ↑ Karpman D, Loos S, Tati R, Arvidsson I (February 2017). "Haemolytic uraemic syndrome". J. Intern. Med. 281 (2): 123–148. doi:10.1111/joim.12546. PMID 27723152.